Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics. - Aguirre LE; Bewersdorf JP; Liu Y; Shallis RM; Boussi L; Zucenka A; Garciaz S; Bystrom RP; DeAngelo DJ; Stone RM; Luskin MR; Garcia JS; et al. (Blood neoplasia, 2026)